ArticleFrontiers in immunology2026
Multi-omics integration and
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory disease with complex pathogenesis. This study aims to screen out key molecular markers and potential therapeutic targets through multi-omics data integration. Methods: Single-cell RNA sequencing data (GSE276503) and transcriptome data (GSE136825, GSE179265) from the GEO database were integrated. Quality control, normalization, clustering, annotation, multi-omics Integration and in Vitro Validation were performed. Results: 4460 differentially expressed genes and 732 hub genes were identified. MR yielded 1673 disease-related genes. After integrating with druggable genes, 43 candidate genes were screened, and they were enriched in complement/coagulation cascades and hematopoietic cell lineage pathways. Machine learning identified three key genes: IL4R and IMPA2 (upregulated in CRSwNP) and PRR4 (downregulated). Immune analysis showed increased monocytes, M2 macrophages, and neutrophils, with decreased memory CD4 T cells in CRSwNP. We constructed a ceRNA network around the key genes and identified transcription factors including GATA2. Drug prediction yielded 26 potential drugs, with molecular docking confirming strong binding of raloxifene (IL4R), luteolin (IMPA2), and metronidazole (PRR4). MR preliminarily suggested IL4R and IMPA2 as potential risk factors and PRR4 as a potential protective factor for CRSwNP. The co-location analysis further evaluated the association between genetic variation of key genes and CRSwNP. Knockdown of IL4R or IMPA2, as well as overexpression of PRR4, significantly attenuated lipopolysaccharide (LPS)-induced cellular injury by reducing apoptosis, suppressing inflammatory responses, and restoring epithelial barrier integrity (all P < 0.001). These findings confirmed the protective effects of targeting these key genes against CRSwNP-related inflammation and epithelial dysfunction. Conclusion: This multi-omics approach identified three key genes in CRSwNP pathogenesis and their regulatory mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.